Pharmacological strategies for treating social anxiety disorder in adults: a systematic review of studies published since 2015
Open accessThe DOI matches its Crossref record; 90 of the 90 references it cites were found in a registry or an index; none of the 106 sources its claims cite is checked for support yet.
Abstract
Introduction Social anxiety disorder (SAD) is a common and disabling mental disorder that follows a chronic course unless it is treated with effective treatments. This systematic review examines randomized controlled trials (RCTs) of pharmacological treatments for adults with SAD published since 2015. Methods This review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Search was conducted on PubMed, Scopus, Web of Science, and PsycINFO. Risk of bias of the included studies was assessed using the Cochrane risk of bias tool for randomized trials. Results Eighteen RCTs were included. Selective serotonin reuptake inhibitors (SSRIs) were the most investigated pharmacological intervention, either as monotherapy or in combination with cognitive behavioral therapy (CBT). More recent drugs show promising results include cannabidiol and d-cycloserine. Conclusion When CBT is unavailable, SSRIs are the first-line pharmacological treatment for SAD based on current evidence. However, response rates vary substantially. We recommend a personalized approach that includes patient preference and treatment accessibility.
Overview
CoChat Summary
TL;DR
This PRISMA-guided systematic review synthesized 18 randomized controlled trials published since 2015 on pharmacological treatment of social anxiety disorder (SAD) in adults, finding that SSRIs remain the best-supported option, alone or combined with CBT. The authors recommend SSRIs as first-line pharmacotherapy when CBT is unavailable, but emphasize personalized, patient-preference-driven care given variable response rates and weak follow-up effects.
Key findings
- Of 18 included RCTs, more than half showed pharmacological interventions (alone or combined with psychotherapy) outperformed control conditions such as placebo or waiting list; 10 studies tested pharmacotherapy alone, 6 tested pharmacotherapy plus psychotherapy, and 4 tested augmentation of exposure therapy.
- SSRIs were the most investigated class (6 monotherapy studies); only one (Nordahl et al.) found no difference from placebo on the Fear of Negative Evaluation Questionnaire at end of treatment and 12-month follow-up. Asakura et al. found both 10 mg and 20 mg escitalopram reduced symptoms after 12 weeks versus placebo, with side effects including nausea, somnolence, and ejaculation problems.
- Augmentation strategies mostly failed: only Smits et al. found DCS enhanced exposure therapy at 3-month follow-up when given before or after sessions (not when given based on session success); testosterone (0.5 ml), scopolamine, and 300 mg CBD showed no advantage over placebo.
- Risk of bias (RoB 2): 5 studies low risk, 7 some concerns, 6 high risk, often due to unclear randomization, missing-data reporting, or absent preregistration.
Methods
- Systematic review following PRISMA, registered in PROSPERO (CRD420251122423); searches of PubMed, Scopus, Web of Science, and PsycINFO for articles published January 2015–August 2025.
- Inclusion criteria: original peer-reviewed RCTs, adult samples (>18 years), diagnosed social anxiety as primary outcome, pharmacological intervention alone or combined with a non-pharmacological intervention; reviews, meta-analyses, animal studies, and mixed-age samples were excluded. No language restrictions.
- From 3,351 records (2,805 after duplicate removal), 72 full texts were assessed and 18 studies included; risk of bias assessed with Cochrane RoB 2 by two independent raters, visualized with ROBVIS.
Limitations
- Stated by the paper: many included trials had relatively small samples, limiting generalizability; effectiveness at follow-up was unreliable in some studies; many RCTs lacked screening for autism spectrum symptoms, which may affect treatment recommendations; the review did not include studies on SNRIs, anticonvulsants, benzodiazepines, or MAOIs, possibly reflecting reduced research focus on second- and third-line treatments.
- Evident from the text: several conclusions rest on single small trials (e.g., ketamine n=18; Yoshinaga 21 vs 21), and six of 18 studies were rated high risk of bias, so pooled efficacy claims should be read cautiously.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 100 Not checked · 30 Own results and interpretations
In the paper
“however, no significant differences were found between the SSRI and GC-MRT group.”
§ 3. Results > 3.1. Pharmacotherapy alone
What the sources say
- Not matchedcites [Citation35]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“four investigated the use of substances (e.g. d-cycloserine) [Citation37] as augmentation strategies for exposure-based interventions”
What the sources say
- Not matchedcites [Citation37]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
In the paper
“Results showed significant decrease in symptoms in the SSRI group compared to the waiting-list group”
§ 3. Results > 3.1. Pharmacotherapy alone
What the sources say
- Not matchedcites [Citation35]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
None of the sources cited for this claim have been checked yet.
In the paper
“Specifically, patients with SAD receiving SSRIs who were accurately informed about the potential therapeutic effect showed larger symptom reduction than those who received SSRIs described as active placebo.”
§ 3. Results > 3.1. Pharmacotherapy alone
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“Results showed that both 10 mg and 20 mg doses were effective in reducing symptoms after 12 weeks compared to placebo.”
§ 3. Results > 3.1. Pharmacotherapy alone
What the sources say
- Not matchedcites [Citation38]
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Not matched
63 more claims
Create a free account to see all 132 claims and every source verdict.
- Probably not a substantial claim. 45
- It may state two separate claims as one. 34
- The quote only partly states this claim. 2
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ 3. Results > 3.1. Pharmacotherapy alone
“Among the studies examining pharmacotherapy alone, six investigated the efficacy of SSRIs [Citation35,Citation38–42].”
§ 3. Results > 3.2. Pharmacotherapy combined with psychotherapy
“Yoshinaga et al. [Citation42] studied the combination of CBT with usual care, consisting of pharmacotherapy including antidepressants and anxiolytic, in a sample of 21 patients with SAD who had not responded to previous intervention with SSRIs.”
Citations
Cites
RoB 2: a revised tool for assessing risk of bias in randomised trials
Sterne, J. A. C., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., Cates, C. J., Cheng, H.-Y., Corbett, M. S., Eldridge, S. M., et al. (2019) · BMJ · doi:10.1136/bmj.l4898 · Cited by 34,787
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2022) · doi:10.1176/appi.books.9780890425787 · Cited by 23,476
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579 · cited 1×
“A visualization of the risk of bias assessment was generated using the ROBVIS online tool [34].”
A cognitive-behavioral model of anxiety in social phobia
Rapee, R. M., & Heimberg, R. G. (1997) · Behaviour Research and Therapy · doi:10.1016/s0005-7967(97)00022-3 · Cited by 2,987 · cited 1×
“Psychosocial models [e.g., 2–4] posit that SAD is maintained by a wish to fulfill societal standards which are perceived as unachievably high.”
Hofmann, S. G. (2007) · Cognitive Behaviour Therapy · doi:10.1080/16506070701421313 · Cited by 1,064
Self-citationMayo-Wilson, E., Dias, S., Mavranezouli, I., Kew, K., Clark, D. M., Ades, A. E., & Pilling, S. (2014) · The Lancet Psychiatry · doi:10.1016/s2215-0366(14)70329-3 · Cited by 680 · cited 2×
“Therefore, consistent with previous literature [29], SSRIs show the clearest efficacy and represent the most extensively studied drug class in the last years.”
Behavioral treatment of childhood social phobia.
Beidel, D. C., Turner, S. M., & Morris, T. L. (2000) · Journal of Consulting and Clinical Psychology · doi:10.1037//0022-006x.68.6.1072 · Cited by 518
Anxiety disorders and GABA neurotransmission: a disturbance of modulation
Gauthier, I., & Nuss, P. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s58841 · Cited by 466
Phenelzine vs Atenolol in Social Phobia: A Placebo-Controlled Comparison
Liebowitz, M. R., Schneier, F., Campeas, R., Hollander, E., Hatterer, J., Fyer, A., Gorman, J., Papp, L., Davies, S., Gully, R., et al. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.49.4.290 · Cited by 444 · cited 1×
“Other pharmacological models supported by animal and human research implicate the dopamine system, as evidenced by the effectiveness of monoamine oxidase inhibitors (MAOIs) [10].”
Turner, S., Mota, N., Bolton, J., & Sareen, J. (2018) · Depression and Anxiety · doi:10.1002/da.22771 · Cited by 432
Research works printed but not linked: 2
- Clark DM, Wells A. A cognitive model of social phobia. In: Heimberg R, Liebowitz M, Hope D Schneier F, editors. Social phobia: diagnosis, assessment and treatment. New York (NY): Guilford Press; 1995. p. 69–93.
- Anxiety and Depression Association of America. Clinical practice review for social anxiety disorder [Internet]. Anxiety and Depression Association of America. 2015 [cited 2025 Jul 3] Available from: https://adaa.org/resources-professionals/clinical-practice-review-social-anxiety#:~:text=Cognitive%2Dbehavioral%20therapy%20(CBT) usually%2012%20to%2024%20sessions
Cited by
Park, S., & Park, S. (2026) · Social Sciences · doi:10.3390/socsci15090579
Laizane, P., Ritola, V., Smith, C. B., Saarni, S. E., Rutan, M. L., Karpov, B., Pihlaja, S., Stenberg, J., & Joffe, G. (2026) · Journal of Medical Internet Research · doi:10.2196/85676
Metadata
- Authors
- Andreoli, G., Kasch, C., Lindsay, C. E., & Hofmann, S. G.
- Affiliations
- Philipps University of Marburg (DE)
- Corresponding author
- Hofmann, Stefan G.
- Venue
- Expert Review of Neurotherapeutics
- Publisher
- Informa UK Limited
- Published
- 2025-12-17
- Volume
- 26
- Issue
- 2
- Pages
- 185-196
- ISSN
- 1473-7175 (ISSN-L)
- 1744-8360
- OpenAlex
- W4417305319
- Semantic Scholar
- 7e13f63190735dc0fa0b54b0b177cb0a113a8c3e
- Cited by
- 2
- References
- 88
- Citations by year
- 2026: 2
- FWCI
- 0.33
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Review of Neurotherapeutics (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- Alexander von Humboldt Foundation
- Hessische Ministerium für Wissenschaft und Kunst
- LOEWE program of the Hessian Ministry of Science and Arts
- Deutsche Forschungsgemeinschaft
- Excellence Cluster E×C3066 ‘The Adaptive Mind.’
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- social anxiety disorder, pharmacotherapy, selective serotonin reuptake inhibitors, cognitive behavioral therapy, cannabidiol, D-cycloserine, combination therapy, adults, personalized treatment
- MeSH terms
- Phobia, Social, Adult, Humans, Anti-Anxiety Agents, Cognitive Behavioral Therapy, Randomized Controlled Trials as Topic, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological strategies for treating social anxiety disorder in adults: a systematic review of studies published since 2015. https://app.cochat.ai/papers/10.1080/14737175.2025.2604303
- The paper
- Andreoli, G., Kasch, C., Lindsay, C. E., & Hofmann, S. G. (2026). Pharmacological strategies for treating social anxiety disorder in adults: a systematic review of studies published since 2015. Expert Review of Neurotherapeutics. https://doi.org/10.1080/14737175.2025.2604303
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.